γ-Secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment

Journal of Neurochemistry

Volumn 121, Issue 2, 2012, Pages 277-286

  Li, Ting ^a   Huang, Yunhong ^a,c   Jin, Shiyi ^a   Ye, Liang ^a   Rong, Na ^a   Yang, Xiujuan ^a   Ding, Yu ^a   Cheng, Ziqiang ^a   Zhang, Jinqiang ^a   Wan, Zehong ^a   Harrison, David C ^b,d   Hussain, Ishrut ^b,e   Hall, Adrian ^b,f   Lee, Daniel Hong Seng ^a,g   Lau, Lit Fui ^a   Matsuoka, Yasuji ^a,h  

^a GLAXOSMITHKLINE   (China)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d Takeda Cambridge Ltd   (United Kingdom)

^e MERCK SERONO S A   (Switzerland)

^f EISAI CO LTD   (Japan)

^g Roche R and D Center China   (China)

^h GlaxoSmithKline   (Singapore)

Author keywords

secretase inhibitor; secretase modulator; Alzheimer's disease; Amyloid ; C terminal fragment

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; GAMMA SECRETASE INHIBITOR; NOTCH RECEPTOR; SEMAGACESTAT;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME REGULATION; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN SYNTHESIS; RAT; REBOUND; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

ALANINE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; AREA UNDER CURVE; AZEPINES; CELL LINE; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME INHIBITORS; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEURONS; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

RATTUS;

EID: 84862792622     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2011.07560.x     Document Type: Article

References (43)

1. Bateman R. J., Siemers E. R., Mawuenyega K. G. et al. (2009) A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann. Neurol. 66, 48-54.
2. Burton C. R., Meredith J. E., Barten D. M. et al. (2008) The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression. J. Biol. Chem. 283, 22992-23003.
3. Cook J. J., Wildsmith K. R., Giberto D. B. et al. (2010) Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J. Neurosci. 30, 6743-6750.
4. Czirr E., Cottrell B. A., Leuchtenberger S. et al. (2008) Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase. J. Biol. Chem. 283, 17049-17054.
5. Dovey H. F., John V., Anderson J. P. et al. (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem. 76, 173-181. (Pubitemid 32044380)
6. Eatherton A. J., Giblin G. M. P., Hall A., Johnson M. R., Le J., Mitchell W. L., Myatt J., Norton D. and Price H. S. (2009) Pyridazine derivatives for inhibiting beta amyloid peptide production. [EP2008/063950]
7. Eli Lilly News Release (2010) Lilly halts development of semagacestat for Alzheimer's disease based on preliminary results of phase iii clinical trials; available at: http://newsroom.lilly.com/releasedetail.cfm?releaseid=499794
8. Fleisher A. S., Raman R., Siemers E. R. et al. (2008) Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch. Neurol. 65, 1031-1038.
9. Galasko D. R., Graff-Radford N., May S. et al. (2007) Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis. Assoc. Disord. 21, 292-299. (Pubitemid 350307433)
10. Green R. C., Schneider L. S., Amato D. A., Beelen A. P., Wilcock G., Swabb E. A. and Zavitz K. H. (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302, 2557-2564.
11. Hall A., Elliott R. L., Giblin G. M., Hussain I., Musgrave J., Naylor A., Sasse R. and Smith B. (2010) Piperidine-derived gamma-secretase modulators. Bioorg. Med. Chem. Lett. 20, 1306-1311.
12. Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
13. Hawkins J., Harrison D. C., Ahmed S. et al. (2011) Dynamics of Aβ42 reduction in plasma, CSF and brain of rats treated with the γ-secretase modulator, GSM-10h. Neurodegener. Dis. 8, 455-464.
14. Hemming M. L., Elias J. E., Gygi S. P. and Selkoe D. J. (2008) Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements. PLoS Biol. 6, e257.
15. Herreman A., Serneels L., Annaert W., Collen D., Schoonjans L. and De S. B. (2000) Total inactivation of gamma-secretase activity in presenilin-deficient embryonic stem cells. Nat. Cell Biol. 2, 461-462.
16. Hyslop P. A., May P. C., Audia J. E., Calligaro D. O., McMillian C. L., Garner C. O., Cramer J. W., Gitter B. D., Porter W. J. and Nissen J. S. (2004) Reduction in a-beta(1-40) and A-beta(1-42) in CSF and plasma in the beagle dog following acute oral dosing of the gamma secretase inhibitor, LY450139. Neurobiol. Aging 25, S147.
17. Ikeda K., Urakami K., Arai H. et al. (2000) The expression of presenilin 1 mRNA in skin fibroblasts and brains from sporadic Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 11, 245-250. (Pubitemid 30665926)
18. Imbimbo B. P., Panza F., Frisardi V., Solfrizzi V., D'Onofrio G., Logroscino G., Seripa D. and Pilotto A. (2011) Therapeutic intervention for Alzheimer's disease with gamma-secretase inhibitors: still a viable option? Expert. Opin. Investig. Drugs 20, 325-341.
19. Kushida I., Doi E., Ito K. and Nakamura T. (2009) Salts of cynnamide compound or solvates thereof. [US 2009/0048448 A1]
20. Lanz T. A., Hosley J. D., Adams W. J. and Merchant K. M. (2004) Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo -6,7-dihydro-5H-dibenzo[ b,d]azepin-7-yl]-L-alaninamide (LY-411575). J. Pharmacol. Exp. Ther. 309, 49-55. (Pubitemid 38393113)
21. Lanz T. A., Karmilowicz M. J., Wood K. M. et al. (2006) Concentration- dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J. Pharmacol. Exp. Ther. 319, 924-933.
22. Li T., Wen H., Brayton C. et al. (2007a) Epidermal growth factor receptor and notch pathways participate in the tumor suppressor function of gamma-secretase. J. Biol. Chem. 282, 32264-32273. (Pubitemid 350106457)
23. Li T., Wen H., Brayton C. et al. (2007b) Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities. J. Neurosci. 27, 10849-10859. (Pubitemid 47535873)
24. Maillard I., Adler S. H. and Pear W. S. (2003) Notch and the immune system. Immunity 19, 781-791. (Pubitemid 37542299)
25. Mathews P. M., Cataldo A. M., Kao B. H. et al. (2000) Brain expression of presenilins in sporadic and early-onset, familial Alzheimer's disease. Mol. Med. 6, 878-891.
26. Michener M. S., Holahan M. A., Giberto D. B. et al. (2006) Nonhuman primate model for prediction of human Abeta effects. Targeting gamma-secretase: effects of enzyme inhibition vs. modulation of cleavage specificity on CSF and plasma Abeta in conscious rhesus monkeys. Alzheimers Dement. 2, S252.
27. Milano J., McKay J., Dagenais C., Foster-Brown L., Pognan F., Gadient R., Jacobs R. T., Zacco A., Greenberg B. and Ciaccio P. J. (2004) Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol. Sci. 82, 341-358. (Pubitemid 39485346)
28. Morales-Corraliza J., Mazzella M. J., Berger J. D., Diaz N. S., Choi J. H., Levy E., Matsuoka Y., Planel E. and Mathews P. M. (2009) In vivo turnover of tau and APP metabolites in the brains of wild-type and Tg2576 mice: greater stability of sAPP in the beta-amyloid depositing mice. PLoS ONE 4, e7134.
29. Peretto I. and La P. E. (2008) Gamma-secretase modulation and its promise for Alzheimer's disease: a medicinal chemistry perspective. Curr. Top. Med. Chem. 8, 38-46. (Pubitemid 351791045)
30. Rochette M. J. and Murphy M. P. (2002) Gamma-secretase: substrates and inhibitors. Mol. Neurobiol. 26, 81-95.
31. Saura C. A., Choi S. Y., Beglopoulos V. et al. (2004) Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42, 23-36. (Pubitemid 38456965)
32. Siemers E., Skinner M., Dean R. A., Gonzales C., Satterwhite J., Farlow M., Ness D. and May P. C. (2005) Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin. Neuropharmacol. 28, 126-132. (Pubitemid 40923411)
33. Siemers E. R., Quinn J. F., Kaye J. et al. (2006) Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66, 602-604. (Pubitemid 43739900)
34. Siemers E. R., Dean R. A., Friedrich S., Ferguson-Sells L., Gonzales C., Farlow M. R. and May P. C. (2007) Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin. Neuropharmacol. 30, 317-325. (Pubitemid 350307310)
35. Smith M. J., Sharples R. A., Evin G. et al. (2004) Expression of truncated presenilin 2 splice variant in Alzheimer's disease, bipolar disorder, and schizophrenia brain cortex. Brain Res. Mol. Brain Res. 127, 128-135. (Pubitemid 39078599)
36. Sommer B. (2002) Alzheimer's disease and the amyloid cascade hypothesis: ten years on. Curr. Opin. Pharmacol. 2, 87-92.
37. Stachel S. J., Coburn C. A., Steele T. G. et al. (2004) Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). J. Med. Chem. 47, 6447-6450. (Pubitemid 39657304)
38. Stanger B. Z., Datar R., Murtaugh L. C. and Melton D. A. (2005) Direct regulation of intestinal fate by Notch. Proc. Natl Acad. Sci. USA 102, 12443-12448. (Pubitemid 41266378)
39. Suzuki N., Cheung T. T., Cai X. D., Odaka A., Otvos Jr L., Eckman C., Golde T. E. and Younkin S. G. (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264, 1336-1340.
40. Weggen S., Eriksen J. L., Das P. et al. (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212-216. (Pubitemid 33051236)
41. Wong G. T., Manfra D., Poulet F. M. et al. (2004) Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279, 12876-12882. (Pubitemid 38445862)
42. Yang M. S., Hong J. S., Kim S. T., Lee K. Y., Park K. W., Kwon S. T., Kweon D. H., Koh Y. H., Gaiano N. and Yoon K. (2011) Among γ-secretase substrates Notch1 alone is sufficient to block neurogenesis but does not confer self-renewal properties to neural stem cells. Biochem. Biophys. Res. Commun. 404, 133-138.
43. Zhang L., Song L., Terracina G., Liu Y., Pramanik B. and Parker E. (2001) Biochemical characterization of the gamma-secretase activity that produces beta-amyloid peptides. Biochemistry 40, 5049-5055. (Pubitemid 32332551)